Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
160
resultados
Última actualización
09/08/2026 [07:33:00]
Resumen de: AU2025213908A1
A compound specifically binding to an α-synuclein aggregate, and a preparation method therefor and the use thereof. Specifically, the compound binding to the α-synuclein aggregate comprises compounds as shown in formula A or sub-general formulas thereof, or stereoisomers, pharmaceutically acceptable salts, solvates or stable isotope variants thereof. The compound is a small molecule tracer, which can specifically recognize the α-synuclein aggregate, and can be used for the preparation of a drug for the treatment or diagnosis of neurodegenerative diseases (such as Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, Alzheimer's disease, amyotrophic lateral sclerosis, progressive supranuclear palsy and progressive muscular atrophy) related to the α-synuclein aggregate and other misfolded proteins.
Resumen de: AU2026207969A1
ALS TREATMENT USING INDUCED REGULATORY T (iTREG) CELLS The present disclosure provides methods for treating ALS using pentostatin and cyclophosphamide treatment followed by TREG and/or TREG/Th2 hybrid cells from dedifferentiated T cells. The present disclosure further provides methods for producing TREG and TREG/Th2 hybrid cells from de-differentiated T cells, said TREG and TREG/Th2 hybrid cells, populations thereof and compositions thereof. Methods for producing de-differentiated T cells, said de-differentiated T cells, populations thereof and compositions thereof are also provided. ul u l
Resumen de: TW202521108A
Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
Resumen de: GB2703562A
A phenoxazine, chromenothiazole, xanthene or thioxanthone compound of formula I or a pharmaceutically acceptable salt, hydrate or solvate thereof for use in a method of treatment or prophylaxis of a tauopathy or a disease of tau protein aggregation: wherein: R1 is -H, C1-4alkyl, halogenated C1-4alkyl, ORO1, C(=O)ORO2 or C(=O)NRN1RN2; R2 is H, halo, C1-4alkyl, NO2, OH or OC1-4alkyl; or R1 and R2, together with the atoms to which they are bound, form a fused phenylene group; R3 is H, halo, -ORO4, or -NRN3RN4; RN3 and RN4 are H, C1-4alkyl or -C(=O)R’, where R’ is C1-4alkyl; R4 is selected from H, halo, C1-4alkyl, halogenated C1-4alkyl, and -ORO5; RO1, RO2, RO4, RO5, RN1 and RN2 are H or C1-4alkyl; X is O; Y is N, N-oxide, or C-R5; and ring ‘A’ is a fused phenylene of formula A1 or a fused aminothiazole of formula A2; or X is S; Y is C=O; and ring A is a fused phenylene of formula A3: wherein W is O or N+ substituted with H or C1-4alkyl; and the remaining groups are as defined herein. The compounds may be useful in the treatment of Alzheimer’s disease. Compounds prepared include N-ethyl-N-2-(piperidin-1-yl)-6H-chromeno2,3-dthiazol-6-ylideneethanaminium perchlorate. See generic formula I at page 5
Resumen de: AU2024353744A1
Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
Resumen de: GB2703561A
The present invention relates to a method of introducing a vector comprising a nucleotide sequence encoding a Kv7.3 ion channel subunit to a lower urinary tract (LUT) neuron and expressing or overexpressing the Kv7.3 ion channel subunit, such that it forms functional ion channels. The method can additionally include a step of administering a neuromodulatory drug. Also disclosed is a gene therapy vector, comprising a nucleotide sequence encoding a Kv7.3 ion channel subunit, wherein the vector selectively transduces the target LUT neuron. Further disclosed is an AAV viral particle gene therapy vector comprising an AAV capsid and a nucleotide sequence encoding a Kv7.3 ion channel subunit. The method can be used to treat a neurological disorder, selected from; spasticity, Parkinson's disease, multiple sclerosis, stroke, traumatic brain injury, spinal cord injury, motor neuron disease, spina bifida, transverse myelitis, HTLV-1 associated neurological conditions, and cerebral palsy. The neuromodulatory drug is selected from; Retigabine/Ezogabine and derivatives thereof, BHV-7000 and Xen496, Xen 1101, flupirtine, diclofenac, BMS-204352, meclofenamic acid, ETX-123 and linopirdine. A use of a neuromodulatory drug in the treatment of bladder musculature dysfunction (BMD), such as detrusor sphincter dyssynergia (DSD) or OAB-NC is also disclosed. Fig. 1
Resumen de: WO2025072438A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective SGK1 inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating disorders associated with serum- and glucocorticoid-regulated kinase 1 (SGK1) activity, such as cardiovascular disorders, fibrotic diseases, metabolic diseases, immune and inflammatory diseases, neurological disorders, and cancer, by using the compounds and pharmaceutical compositions.
Resumen de: EP4786464A1
Disclosed are a compound represented by formula (A-I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof as a glutamine cyclase inhibitor, a preparation method therefor, a pharmaceutical composition comprising the compound represented by formula (A-I) or the stereoisomer thereof or the pharmaceutically acceptable salt thereof, and a use of the compound represented by formula (A-I) or the stereoisomer thereof or the pharmaceutically acceptable salt thereof in preventing or treating diseases or conditions mediated by QPCT and/or QPCTL, including neurodegenerative diseases.
Resumen de: EP4786463A2
0001 The invention relates to new proline derivatives of formula (I) as cGAS inhibitors,
wherein
wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are defined as in claim 1,
and prodrugs or pharmaceutically acceptable salts of these compounds
for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).
Resumen de: US20260217699A1
0000 The invention provides berberine tauroursodeoxycholate (BTUDC), pharmaceutical compositions and methods of use thereof for the treatment, reduction and/or prevention of Parkinson's disease, or an associated disease and disorder, as monotherapy or in combination with other agents or as an adjuvant. The invention further provides pharmaceutical compositions and methods of use of berberine (BBR) and tauroursodeoxycholic acid (TUDCA) for the treatment, reduction and/or prevention of Parkinson's disease, or an associated disease and disorder, as monotherapy or in combination with other agents or as an adjuvant.
Resumen de: US20260216372A1
The disclosure relates to compositions and methods for altering, e.g., enhancing, the expression of GCase proteins, whether in vitro and/or in vivo. Such compositions include delivery of an adeno-associated viral (AAV) particle. The compositions and methods of the present disclosure are useful in the treatment of subjects diagnosed with, or suspected of having Parkinson's Disease (PD), Gaucher Disease (GD), Dementia with Lewy Bodies (DLB), or related condition resulting from a deficiency in the quantity and/or function of GBA1 gene product or associated with decreased expression or protein levels of GCase protein.
Resumen de: US20260219283A1
0000 Synucleinopathies are a group of neurodegenerative diseases including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). These diseases are characterized by the aggregation and deposition of α-synuclein (α-syn) in Lewy bodies (LBs) in PD and DLB or as glial cytoplasmic inclusions in MSA. In healthy brains, only ~4% of α-syn is phosphorylated at Ser129 (pS129-α-syn), whereas >90% pS129-α-syn may be found in LBs. Embodiments of the invention include a duplex assay for both total α-synuclein and pS129-α-synuclein, which allows measuring both analytes in the same sample, leading to substantial saving in sample volume. The assays can be widely used in methods for detecting pS129-α-syn in biomedical studies including when only a limited volume of sample is available and high sensitivity is required, offering new opportunities for diagnostic biomarkers, monitoring disease progression, and quantifying outcome measures in clinical trials.
Resumen de: US20260217678A1
Indazole- and azaindazole-substituted octahydrocyclopentacpyrrole and hexahydrocyclopentacpyrrole compounds are inhibitors of LRRK2. The compounds and their pharmaceutical compositions may be used in the treatment of CNS disorders such as familial/genetic and/or sporadic Parkinson's disease, a tauopathy, or Alzheimer's disease. Indazole- and azaindazole-substituted octahydrocyclopentacpyrrole and hexahydrocyclopentacpyrrole compounds of formula (I) are inhibitors of LRRK2. The compounds and their pharmaceutical compositions may be used in the treatment of CNS disorders such as familial/genetic and/or sporadic Parkinson's disease, a tauopathy, or Alzheimer's disease.
Resumen de: US20260216139A1
Methods for regulating aberrant glia-directed engulfment and active pruning of Neuronal Receptive Endings (NRE) are provided. Such methods comprise contacting a neuronal and/or glia cell with an effective amount of a composition which is effective in modulating at least one gene and/or protein associated with glia-directed engulfment and active pruning of Neuronal Receptive Endings. Such methods are useful in treating neurological disorders such as Parkinson's disease.
Resumen de: WO2026158729A2
Provided in the present application are a pathogenic factor of neurodegenerative diseases and the use thereof. The pathogenic factor of neurodegenerative diseases is a PSAP-GPR37-IL-6 signaling axis. The present application specifies for the first time the action mechanism of the PSAP-GPR37-IL-6 signaling axis as a pathogenic factor of neurodegenerative diseases (especially Parkinson's disease), and reveals that oligodendrocytes regulate the molecular pathway of neuroinflammation and neurodegenerative changes via the signaling axis, thus filling the research gap in the prior art regarding the participation of oligodendrocytes in the pathogenesis of PD.
Resumen de: WO2026161463A1
Disclosed is a method of diagnosing a subject with ALS, the method including measuring the amount of OxPL on apolipoprotein E, E2, E3 and/or E4.
Resumen de: US20260216237A1
0000 Provided herein are methods and compositions for the treatment of ALS using chlorite or a pharmaceutical composition comprising sodium chlorite, for a target ALS patient population. Also provided herein are methods for identifying a target ALS patient population likely to be responsive to treatment with chlorite or a pharmaceutical composition comprising sodium chlorite, the methods including identifying ALS patients with elevated plasma C-reactive protein (CRP) levels and/or patients age 40-65, sporadic ALS pathology, or combinations thereof.
Resumen de: US20260216351A1
Disclosed are compositions and methods of use for treating neuronal diseases such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS). In certain embodiments, a flavonoid, such as apigenin, is administered alone or in a pharmaceutical preparation via the nasal olfactory route. In some embodiments, the composition further comprises a porosome complex for reconstitution into neural cells. In additional embodiments, a synthetic blood-brain barrier traversing peptide is included, wherein the peptide is engineered to mimic a domain of ATP1A3 and/or Tubulin, thereby enhancing therapeutic efficacy in restoring secretory and metabolic function in neural tissue.
Resumen de: WO2026161742A1
Methods and materials for identifying mammals (e.g., humans) as having, or being likely to have or to develop, Alzheimer's disease are provided herein. In some cases, methods and materials for stratifying mammals with Alzheimer's disease are provided herein.
Resumen de: WO2026159574A1
A synaptic connector that promotes the formation of dopamine synapse, the synaptic connector being a molecule capable of connecting a deleted in colorectal cancer (DCC) protein present on the surface of the front part of dopamine synapse and a delta-type glutamate receptor (GluD) protein present on the surface of the rear part of dopamine synapse.
Resumen de: WO2026158687A1
The present invention relates to the technical field of antibody drugs, and in particular, to an anti-N3pE amyloid-β antibody and the use thereof, and a pharmaceutical composition containing the anti-N3pE amyloid-β antibody. The anti-N3pE amyloid-β antibody exhibits a significantly excellent affinity, stability and specificity. In addition, further provided is the use of the anti-N3pE amyloid-β antibody for treating diseases caused by amyloid-β (e.g., Alzheimer's disease, Down syndrome, cerebral amyloid angiopathy, etc.).
Resumen de: WO2026158331A1
Provided are a traditional Chinese medicine for preventing and/or treating Parkinson's disease and a method for preparing same. The traditional Chinese medicine comprises the following raw materials in parts by weight: 10-15 parts of Gastrodiae Rhizoma, 5-10 parts of Juglandis Semen, 30-40 parts of honey, 30 parts of Rosa roxburghii, and 5-8 parts of lemon. The traditional Chinese medicine has significant effects on the prevention and/or treatment of Parkinson's disease, and features simple composition, mild adverse effects, and good drug stability.
Resumen de: EP4782003A1
The present application relates to a novel therapeutic agent for treating Parkinson's disease and a method for treating Parkinson's disease using the same.
Resumen de: WO2025061918A1
The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class Ib molecules) in combination with peptide antigens for the treatment of Parkinson's disease. The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHC class Ib molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating Parkinson's disease.
Nº publicación: EP4780840A1 29/07/2026
Solicitante:
JULIUS MAXIMILIANS UNIV WUERZBURG IN VERTRETUNG DES FREISTAATES BAYERN [DE]
Julius-Maximilians-Universit\u00E4t W\u00FCrzburg, in Vertretung des Freistaates Bayern
Resumen de: TW202530251A
The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class Ib molecules) in combination with peptide antigens for the treatment of neuromyelitis optica (NMO). The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHC class Ib molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating neuromyelitis optica (NMO).
BOPI
Sede Electrónica
